Externally Led Patient-Focused Drug Development Meeting
Learn from the voices of individuals and families affected by FTD: On March 5th, 2021, AFTD will host a virtual Externally Led Patient-Focused Drug Development (EL-PFDD) meeting with representatives of the U.S. Food and Drug Administration.
The meeting begins on Friday, March 5th at 10:00 a.m. To sign in and join the meeting, please go to: https://www.theaftd.org/get-involved/patient-focused-drug-development
| Time | Agenda |
|---|---|
| 10:00 AM | Opening Remarks Susan L-J Dickinson, MSGC, CEO, The Association for Frontotemporal Degeneration (AFTD) |
| 10:10 AM | FDA Welcome Remarks Michelle Campbell, PhD, Sr. Clinical Analyst for Stakeholder Engagement & Clinical Outcomes, Division of Neurology Products, FDA |
| 10:20 AM | Background on FTD Brad Dickerson, MD, Director, Frontotemporal Disorders Unit, Massachusetts General Hospital, Professor of Neurology, Harvard Medical School |
| 10:35 AM | Introduction & Meeting Overview James Valentine, JD, MHS, Meeting Moderator |
| 10:40 AM | Demographic Polling |
| 10:45 AM | Topic 1, Panel 1: Health Effects and Daily Impacts |
| 11:10 AM | Moderated audience discussion and polling James Valentine, JD, MHS, Susan Dickinson, MSGC |
| 12:25 PM | Lunch Break |
| 12:55 PM | Topic 2: Current & Future Approaches to Treatment James Valentine, JD, MHS |
| 1:00 PM | Panel 2A: Perspectives on Sporadic FTD |
| 1:25 PM | Panel 2B: Perspectives on Genetic FTD |
| 1:55 PM | Moderated audience discussion and polling James Valentine, JD, MHS, Susan L-J Dickinson, MSGC |
| 3:15 PM | Meeting Summary Larry Bauer, RN, MA, Hyman, Phelps, & McNamara, P.C. |
| 3:20 PM | Next Steps & Closing Remarks Susan L-J Dickinson, MSGC |
Thank you to our sponsors
Platinum
Gold
Silver
Bronze
